The Application of T1 Mapping in Real-World
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Magnetic Resonance Imaging with Contrast.
- Who it may be relevant to
- Registry conditions: Myocardial Infarction (MI), Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Arrhythmogenic Cardiomyopathy. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Landscape of T1 Mapping for Disease Profiling in a Real-World Cohort
Overview
The goal of this observational study is to create a comprehensive real-world spectrum of T1 mapping measurements across different heart conditions. We aim to establish reference values for how heart tissue characteristics vary in various diseases, which will help doctors better interpret these advanced MRI measurements in clinical practice. The main questions it aims to answer are: What are the normal T1 mapping values for different heart diseases, and how do they compare to healthy hearts? Can we use the simpler "native T1" measurement (without contrast dye) instead of the more complex "ECV" measurement (which requires contrast dye) for diagnosis? Patients with various myocardial conditions will undergo CMR T1 mapping scans. We will analyze the MRI images and clinical records to establish disease-specific reference ranges for T1 mapping parameters, and validate the diagnostic accuracy of T1 mapping
Interventions
- Diagnostic test Magnetic Resonance Imaging with Contrast
Participants in this arm undergo a single, standardized cardiac MRI scan with gadolinium-based contrast agent.
Primary outcome measures
- Ranges of T1 mapping values [Time frame: From enrollment until completion of the last T1 mapping examination, assessed up to 5 years]
Eligibility criteria
Inclusion criteria
- Adult patients (≥18 years) with clinically diagnosed myocardial diseases based on current international guidelines.
- Specific disease categories include:
- Cardiomyopathies (HCM, DCM, RCM, ACM)
- Infiltrative disorders (cardiac amyloidosis, Fabry disease)
- Inflammatory conditions (acute/chronic myocarditis)
- Ischemic heart disease (acute/chronic MI)
- Valvular heart disease (aortic stenosis)
- Arrhythmic conditions (atrial fibrillation)
- Metabolic disorders (iron-overload)
- Neoplastic conditions (cardiac tumors)
- Congenital heart disease
- Post-transplant evaluation
- All diagnoses must be confirmed using established guideline-based criteria:
- Echocardiographic parameters meeting disease-specific cutoffs
- Cardiac MRI findings consistent with current consensus criteria
- Laboratory biomarkers supporting respective diagnoses
- Histopathological confirmation when clinically indicated
Exclusion criteria
- Presence of multiple cardiomyopathy diseases or risk factors simultaneously
- Contraindications to CMR examination
- Poor image quality precluding accurate T1 mapping analysis
- Incomplete clinical data for definitive diagnosis confirmation
- Pregnancy or lactation
- Inability to provide informed consent
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Fuwai Hospital, Chinese Academy of Medical Sciences — Beijing
Identifiers
NCT: NCT07354646 · CMR_T1 mapping